For the year ending 2025-12-31, SRPT had -$304,182K decrease in cash & cash equivalents over the period. -$307,451K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net (loss) income | -713,410 |
| Non-cash inventory write-downs for excess and obsolescence | 165,257 |
| Stock-based compensation | 123,396 |
| In-kind milestone payment to arrowhead pharmaceuticals | 50,000 |
| Depreciation and amortization | 44,521 |
| Loss on investment in arrowhead pharmaceuticals | -17,293 |
| Non-cash write-off of prepaid deposits | 17,041 |
| (gain) loss on debt extinguishment | 16,862 |
| Reduction in the carry amounts of the right of use assets | 13,951 |
| Non-cash interest expense | 13,532 |
| Accretion of investment discount, net | -5,291 |
| Non-cash termination charges | 0 |
| Change in the fair value of derivatives | 0 |
| Impairment of strategic investments | 0 |
| Gain from sale of priority review voucher | 0 |
| Other | -7,055 |
| Decrease (increase) in accounts receivable | -203,755 |
| Increase in inventory | 301,093 |
| Decrease (increase) in manufacturing-related deposits and prepaids | -78,840 |
| (increase) decrease in other assets | 79,784 |
| Increase (decrease) in deferred revenue | 72,051 |
| Increase (decrease) in accounts payable, accrued expenses, lease liabilities and other liabilities | 104,269 |
| Net cash used in operating activities | -205,479 |
| Maturity and sale of available-for-sale securities | 295,871 |
| Acquisition of strategic investments | -245,819 |
| Proceeds from sale of investment in arrowhead pharmaceuticals | 174,095 |
| Purchase of property and equipment | 101,972 |
| Purchase of available-for-sale securities | 44,658 |
| Purchase of intangible assets and other | 7,876 |
| Proceeds from sale of priority review voucher | 0 |
| Net cash provided by (used in) investing activities | 69,641 |
| Repayment of 2027 notes, including debt extinguishment costs | 158,418 |
| Repurchases of common stock, net of excise tax | 25,013 |
| Proceeds from issuance of common stock | 20,000 |
| Debt issuance costs for the august 2025 exchange and december 2025 exchange (defined in note 13) | 17,060 |
| Proceeds from exercise of stock options and purchase of stock under the employee stock purchase program | 18,703 |
| Payments related to revolving credit facility | 4,170 |
| Common stock issuance costs | 2,386 |
| Settlement of capped call share options for 2024 notes | 0 |
| Payment on maturity of 2024 notes | 0 |
| Debt conversion costs for 2024 notes | 0 |
| Net cash (used in) provided by financing activities | -168,344 |
| (decrease) increase in cash and cash equivalents | -304,182 |
| Beginning of year | 1,118,589 |
| End of year | 814,407 |
Sarepta Therapeutics, Inc. (SRPT)
Sarepta Therapeutics, Inc. (SRPT)